EP3148599A1 - Method for preparing neutralized matrix of non-antigenic collagenous material - Google Patents

Method for preparing neutralized matrix of non-antigenic collagenous material

Info

Publication number
EP3148599A1
EP3148599A1 EP15725376.6A EP15725376A EP3148599A1 EP 3148599 A1 EP3148599 A1 EP 3148599A1 EP 15725376 A EP15725376 A EP 15725376A EP 3148599 A1 EP3148599 A1 EP 3148599A1
Authority
EP
European Patent Office
Prior art keywords
matrix
collagenous material
antigenic collagenous
antigenic
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15725376.6A
Other languages
German (de)
French (fr)
Other versions
EP3148599B1 (en
Inventor
Amandine JAILLON
Aurélie SERRERO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sofradim Production SAS
Original Assignee
Sofradim Production SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sofradim Production SAS filed Critical Sofradim Production SAS
Publication of EP3148599A1 publication Critical patent/EP3148599A1/en
Application granted granted Critical
Publication of EP3148599B1 publication Critical patent/EP3148599B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A61L15/325—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding

Definitions

  • the present invention relates to a method for preparing neutralized matrices of non-antigenic collagenous material showing good tensile strength.
  • the invention further relates to matrices obtained by this method and to surgical implants, for example hernia repair implants or haemostats, comprising such matrices.
  • Collagen based matrices in general are particularly useful for the manufacture of implants in the medical field.
  • Such matrices are usually obtained by lyophilisation of a collagen solution. Lyophilization involves a first step during which a solution is frozen in a particular structure, and then a second step, during which a controlled pressure is applied in order to cause sublimation of the water present in the frozen structure. At the end of the sublimation step, only the constituents present in the initial solution remain, thus producing a porous structure.
  • porous structure of such collagen matrices is of particular interest in the manufacture of surgical implants for many reasons.
  • a porous structure favors cell colonization and therefore reconstruction of the biological tissue.
  • the porous structure allows efficiently absorbing biological fluids, like blood.
  • these reinforcing implants and haemostatic patches must also show very good mechanical properties, such as a high tensile strength, and good handling characteristics.
  • collagenous preparations have been suggested for the manufacture of surgical implants. These preparations have comprised dispersions, solutions and gels of collagen, as well as reconstituted and spongy forms of collagen. These preparations were most often prepared by digesting collagen of animal origin with a proteolytic enzyme active under acidic conditions. The collagenous material is solubilised in the acidic media and can be filtered from any debris and insoluble skin components. The solubilised collagen may be reconstituted as a solid, gel or sponge by raising the pH of the solution and stabilising by cross-linking. However, the natural structure of the collagen is lost in the process. The resulting preparations tend to have little or no tensile strength, are amorphous in structure and show a propensity for being reabsorbed, either disappearing from the site of injection or implantation or being replaced by scar tissue.
  • non- antigenic collagenous material are those in which the basic structure of the natural collagen, for example from skin, is maintained, which are substantially free of antigenic non-fibrous tissue proteins and which are substantially free of antigenic polysaccharides, mucopolysaccharides and glycoproteins.
  • the preparation of such non-antigenic collagenous materials is described in GB 1 565 340, US 5, 397, 353 and US 6, 936, 271 .
  • material substantially free of a compound is meant that the material contains less than 5%, preferably less than 1 % in weight of said compound.
  • the preparation of non-antigenic collagenous material may comprise treating fibrous tissue of human or animal origin with two enzymes, one of said enzymes being a proteolytic enzyme which will under certain conditions remove the non-fibrous tissue proteins, and the other of said enzymes being a carbohydrate-splitting enzyme which will under certain conditions remove antigenic polysaccharide, mucopolysaccharides and glycoproteins from the tissue.
  • Non-antigenic collagenous material in particular obtained as described above, has low or absent antigenicity. Any residual antigenicity in the tissue may be removed therefrom by reacting it with a cross- linking agent which will under certain conditions form a link between the terminal amino groups of lysine groups in the tissue.
  • Crosslinking agents may be glutaraldehyde, formalaldehyde and nitrous acid.
  • non-antigenic collagenous material When homografted between individuals of the same species or heterografted between individuals of a different species, non-antigenic collagenous material does not elicit immunological rejection reactions or foreign body reactions.
  • Non-antigenic collagenous material is particularly stable and strong.
  • the original architecture of the collagenous fibrous material is preserved.
  • the telopeptides of the collagen are kept intact. The material is neither solubilised nor denatured in the process so its natural structure is maintained which makes an implant derived from the material feel natural rather than an inert material.
  • Non-antigenic collagenous material is capable of being infiltrated and colonized by the host cells of another individual of the same or different species and revascularized to form a repair implant for example.
  • Non-antigenic collagenous material may be prepared under the form of a sheet material, of a cryomilled powder or also as a powdered lyophilised form.
  • Non-antigenic collagenous material is therefore of particular interest for surgical applications. It would be interesting to provide matrices of non- antigenic collagenous material in order to use them in the manufacture of surgical implants, such as for example hernia repair implants or haemostatic patches.
  • Non-antigenic collagenous material regardless from the form under which it is prepared, is not soluble at neutral pH and may be solubilised in an acidic solution only.
  • the matrices obtained by lyophilisation of these acidic solutions are also acidic.
  • acidic matrices may cause biocompatibility problems with adjacent biological tissue once implanted in a patient body.
  • the Applicant has found that by performing a specific sterilization step on matrices obtained by lyophilisation of an acidic solution of non- antigenic collagenous material, it was possible to efficiently neutralize and sterilize such matrices at the same time, while enhancing their mechanical properties, in particular their tensile strength.
  • a first aspect of the present invention is a method for preparing a neutralized matrix of non-antigenic collagenous material comprising the steps of :
  • the method according to the invention makes it possible to obtain neutralized matrices of non-antigenic collagenous material showing excellent mechanical properties such as tensile strength.
  • the method of the invention allows performing the neutralization and the sterilization of the matrices in a single step.
  • the method of the invention allows therefore saving at least one step in the manufacturing process of a collagen matrices, namely of a matrix of non-antigenic collagenous material.
  • the manufacturing process is therefore rendered particularly simple. Time is saved and opportunities of making mistakes are decreased with respect to a method where the neutralization step and the sterilization step are two separate steps.
  • the matrices of non-antigenic collagenous material obtained by means of the method according to the invention have excellent tensile strength. They also show good handling characteristics.
  • the matrices obtained by the method of the invention are also particularly useful in the manufacture of haemostats such as haemostatic patches.
  • the matrices obtained by the method of the invention may also be used as scaffolds for cell culture.
  • the matrices obtained by the method of the invention may be used on their own or in combination with a textile or with any other element, such as for example a film, a matrix of same or different composition.
  • Another aspect of the invention is a matrix obtained by the method of the invention.
  • the matrices obtained by the method of the invention show in particular a tensile strength much greater than that of matrices prepared according to steps a)-c) above but which have not been sterilized according to step d).
  • An aspect of the invention is therefore a neutralized matrix of non- antigenic collagenous material obtained by the method of the invention.
  • An aspect of the invention is a neutralized matrix of non-antigenic collagenous material obtained by the method of the invention, having a tensile strength, for example measured according to standard ASTM D0638-03 with type IV specimen, at least two times greater, preferably three times greater, than that of the non sterilized matrix.
  • step a) an acidic solution of non-antigenic collagenous material is prepared.
  • non-antigenic collagenous material in the present application, means a collagenous material in which the basic structure of the natural collagen, for example from skin, is maintained, which is substantially free of antigenic non-fibrous tissue proteins and which is substantially free of antigenic polysaccharides, mucopolysaccharides and glycoproteins.
  • the preparation of such non-antigenic collagenous materials is described in GB 1 565 340, US 5, 397, 353 and US 6, 936, 271 .
  • material substantially free of a compound is meant that the material contains less than 5%, preferably less than 1 % in weight of said compound.
  • the preparation of non-antigenic collagenous material may comprise treating fibrous tissue of human or animal origin with two enzymes, one of said enzymes being a proteolytic enzyme which will under certain conditions remove the non-fibrous tissue proteins, and the other of said enzymes being a carbohydrate-splitting enzyme which will under certain conditions remove antigenic polysaccharide, mucopolysaccharides and glycoproteins from the tissue.
  • Non-antigenic collagenous material in particular obtained as described above, has low or absent antigenicity. Any residual antigenicity in the tissue may be removed therefrom by reacting it with a cross- linking agent which will under certain conditions form a link between the terminal amino groups of lysine groups in the tissue.
  • Crosslinking agents may be glutaraldehyde, formalaldehyde and nitrous acid.
  • non-antigenic collagenous material When homografted between individuals of the same species or heterografted between individuals of a different species, non-antigenic collagenous material does not elicit immunological rejection reactions or foreign body reactions.
  • Non-antigenic collagenous material is particularly stable and strong.
  • the original architecture of the collagenous fibrous material is preserved.
  • the telopeptides of the collagen are kept intact. The material is neither solubilised nor denatured in the process so its natural structure is maintained which makes an implant derived from the material feel natural rather than an inert material.
  • Non-antigenic collagenous material is capable of being infiltrated and colonized by the host cells of another individual of the same or different species and revascularized to form a repair implant for example.
  • Non-antigenic collagenous material may be prepared under the form of a sheet material, of a cryomilled powder or also as a powdered lyophilised form.
  • Non-antigenic collagenous material may also preferably be substantially free of cellular elements.
  • the fibrous tissue is purified so that all cellular elements such as sweat glands, sebaceous glands and vascular tissue are removed thus eliminating cyst formation and foreign body reactions when subsequently implanted in a body.
  • Such a purification process is described in US 5, 397, 353.
  • Non-antigenic collagenous material may also preferably be substantially free of lipids and lipid residues.
  • the fibrous tissue may be further treated in order to remove the lipid portions from the tissue, for example by using a selective enzyme such as a lipase or alternatively by solvent extraction using an organic solvent.
  • a selective enzyme such as a lipase
  • solvent extraction using an organic solvent Such a process for removing the lipids and lipid residues from the non-antigenic collagenous material is described in US 5, 397, 353.
  • the fibrous tissue may further be treated by polyisocyanates in order to obtain non-antigenic collagenous material preparations having particularly low cytotoxicity.
  • non-antigenic collagenous material shows a good inertness with respect to adjacent biological tissue when implanted.
  • Non-antigenic collagenous materials suitable as starting compounds for the method according to the invention are for example described in US 5, 397, 353 and US 6, 936, 271 .
  • the acidic solution of step a) of the method according to the invention is generally prepared by solubilization of non-antigenic collagenous material in powder or fibrous form in water.
  • the solution is adjusted to the desired pH, for example by adding chlorhydric acid or acetic acid, either before or after introduction of the non-antigenic collagenous material.
  • the pH of the solution is adjusted to a value ranging from about 2.0 to about 4.0, preferably from about 3.0 to about 3.5, more preferably to about 3.4, for example by adding chlorhydric acid or acetic acid.
  • Such pHs for the solution of step a) make it possible to obtain, in the end, matrices which have particularly good tensile strength.
  • the solution of step a) is a solution of non-antigenic collagenous material in acidic water, the concentration of non-antigenic collagenous material in said solution ranging from 0.1 to 10%, preferably from 0.5% to 3%, and more preferably about 1 % by weight, relative to the total weight of the solution.
  • the solution of the method according to the invention is free of any other polymer than the non-antigenic collagenous material.
  • step b) the acidic solution of non-antigenic collagenous material is poured into a mould in order to form a layer.
  • the mould is in the shape of a rectangle having dimensions compatible with the use of the matrix obtained as all or part of a reinforcing implant for the abdominal wall or of a haemostatic patch.
  • step c) the layer obtained in b) is lyophilized so as to obtain a matrix.
  • matrix is intended to mean a layer which has pores, or gaps, alveoli, holes, orifices, which are evenly or unevenly distributed not only at the surface, but also within the thickness of said layer, and which are more or less interconnected, depending on the lyophilization process used. Such lyophilization processes are known.
  • the layer in step c), is frozen during a time ranging from 3 to 15 hours. In embodiments, in step c), the frozen layer is primary dried during a time ranging from 7 to 15 hours.
  • the matrix obtained by the lyophilization of the layer of acidic solution of non-antigenic collagenous material is acidic, in other words has an acidic extractible pH.
  • an extractible pH may vary from 3 to 5, and for example is 4.
  • step d) the matrix obtained in c) is sterilized with ethylene oxide.
  • the matrix may be preconditioned in order to make sure that it is at a uniform temperature and humidity.
  • the matrix is put in a cell and may be exposed during a determined time, ranging for example from 8 to 15 hours, to a warm and humid environment.
  • the temperature may range from about 28°C to about 32°C.
  • the relative humidity may range from about 50 to about 80%.
  • the cell is evacuated and the ethylene oxide is introduced.
  • the matrix is exposed to ethylene oxide for a time that may range from about 10 to about 1 1 hours. During this time, a certain amount of ethylene oxide, for example from 1 .6 to 2 kg, is injected.
  • the ethylene oxide is injected at a pressure that may range from 70000 Pa to 78000 Pa. The temperature and relative humidity may be the same as in the first stage.
  • ethylene oxide is removed and air replaces the ethylene oxide in the cell .
  • the sterilized matrix of non- antigenic collagenous material may show an extractible pH of about 7.0-7.4.
  • This sterilization step has as a consequence that the pH of the matrix of non-antigenic collagenous material is increased to about 7.0-7.4, in particular is increased from about 3.0-4.0 to about 7.0-7.4.
  • the sterilized matrix is therefore neutralized during the sterilization with the ethylene oxide.
  • the sterilization and the neutralization of the matrix therefore occur in one single step.
  • the method of the invention therefore allows saving an operation step with respect to methods of the prior art in which the sterilization step and the neutralization step are two separate operations.
  • the matrix of non-antigenic collagenous material which has been neutralized and sterilized according to the method of the invention can be part of, or constitute, the whole of a surgical implant, for example an abdominal wall reinforcement or of an haemostatic patch. Indeed, these neutralized and sterilized matrices have excellent tensile strength.
  • a surgical implant such as an abdominal wall reinforcement, for example a hernia repair implant, or an haemostat such as a haemostatic patch, comprising at least one neutralized matrix of non-antigenic collagenous material obtained by the method described above.
  • a hernia repair implant comprising at least one neutralized matrix of non-antigenic collagenous material obtained by the method described above.
  • the hernia repair implant may consist in a neutralized matrix of non-antigenic collagenous material obtained by the method described above.
  • a haemostat comprising at least one neutralized matrix of non-antigenic collagenous material obtained by the method described above.
  • the haemostat may consist in a neutralized matrix of non-antigenic collagenous material obtained by the method described above.
  • Another aspect of the invention is a method for increasing the tensile strength of a matrix of non-antigenic collagenous obtained by:
  • said method comprising the step of sterilizing the acidic matrix obtained in c) with ethylene oxide.
  • Figure 1 is a graph comparing the tensile strengths of a matrix obtained with the method of the invention and of two other matrices not obtained with the method of the invention.
  • Non-antigenic collagenous material similar to that described at example 5 of US 6, 936, 271 , except for the crosslinking step, is provided, under the form of powder.
  • a solution of non-antigenic collagenous material at 1 % (w/w) in water is prepared and adjusted to about pH 4.0 by addition of HCI .
  • the layer is lyophilised for about 24 hours, with a freezing step of 4 hours, and a primary drying step of 8 hours.
  • a matrix of non-antigenic collagenous material is obtained.
  • This matrix is acidic, i.e. this matrix has an extractible pH of about 5.2.
  • the matrix is then sterilized with ethylene oxide according to the following process.
  • the matrix is put in a cell and is exposed during 8-15 hours to a warm and humid environment with the following parameters :
  • the cell In a second stage, the cell is evacuated and the ethylene oxide is introduced. The matrix is exposed to ethylene oxide for approximately 10-1 1 hours. During this time, 1 .6 to 2 kg of ethylene oxide is injected. The ethylene oxide injection pressure ranges from 70000 to 78000 Pa. The temperature and relative humidity are the same as in the first stage. In a third stage, ethylene oxide is removed.
  • the sterilized matrix obtained shows an extractible pH of about 7.0.
  • the sterilization of the matrix with ethylene oxide has led to an increase of the extractible pH of the matrix from about 5.2 to about 7.0.
  • the sterilized matrix of non-antigenic collagenous material is therefore neutralized.
  • a matrix may be used for the manufacture of a surgical implant such as an abdominal reinforcement or a haemostatic patch with no risk that the matrix dissolves or collapses at the contact of a neutral medium such as the biological fluid.
  • the sterilized and neutralized matrix obtained shows very good tensile strength.
  • the sterilized matrix shows a higher tensile strength than the non sterilized matrix.
  • the tensile strengths of the matrix of the present example before sterilization (comparative referenced N/A), after sterilization with ethylene oxide (invention referenced EtO), and of a matrix of same composition of that of the present example but neutralized with ammonia (comparative reference Ammonia) have been measured according to the test described in standard ASTM D0638-03 with type IV specimen.
  • the tensile strength of the matrix obtained by the method of the invention is at least two times, and is even about three times, greater than that of the non sterilized matrix.
  • the tensile strength of the matrix obtained by the method of the invention is about twice greater than that of a matrix neutralized by Ammonia.
  • Non-antigenic collagenous material similar to that described at example 5 of US 6, 936, 271 , except for the crosslinking step, is provided, under the form of powder.
  • a solution of non-antigenic collagenous material at 1 % (w/w) in water is prepared and adjusted to about pH 3.4 by addition of CH 3 COOH.
  • the layer is lyophilised for about 24 hours, with a freezing step of 4 hours, and a primary drying step of 8 hours.
  • a matrix of non-antigenic collagenous material is obtained.
  • This matrix is acidic, i.e. this matrix has an extractible pH of about 5.1 .
  • the matrix is then sterilized with ethylene oxide according to the following process.
  • the matrix is put in a cell and is exposed during 8-15 hours to a warm and humid environment with the following parameters :
  • the cell is evacuated and the ethylene oxide is introduced.
  • the matrix is exposed to ethylene oxide for approximately 10-1 1 hours. During this time, 1 .6 to 2 kg of ethylene oxide is injected.
  • the ethylene oxide injection pressure ranges from 70000 to 78000 Pa.
  • the temperature and relative humidity are the same as in the first stage.
  • ethylene oxide is removed.
  • the sterilized matrix obtained shows an extractible pH of about 7.0- 7.4.
  • the sterilization of the matrix with ethylene oxide has led to an increase of the extractible pH of the matrix from about 5.1 to about 7.0-7.4.
  • the sterilized matrix of non-antigenic collagenous material is therefore neutralized.
  • a matrix may be used for the manufacture of a surgical implant such as an abdominal reinforcement or a haemostatic patch with no risk that the matrix dissolves or collapses at the contact of a neutral medium such as the biological fluid.
  • the tensile strengths of the matrix of the present example before sterilization and after sterilization with ethylene oxide have been measured according to the test described in standard ASTM D0638-03 with type IV specimen.
  • the tensile strength of the matrix obtained by the method of the invention is at least twice, and is even about 2.8 times, greater than that of the non sterilized matrix.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Biophysics (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)

Abstract

The present invention relates to a method for preparing a neutralized matrix of non-antigenic collagenous material comprising the steps of : - a) preparing an acidic solution of non-antigenic collagenous material, - b) pouring the solution of a) into a mould in order to form a layer, - c) lyophilizing the layer of b) in order to obtain an acidic matrix of non-antigenic collagenous material, d) sterilizing the acidic matrix obtained in c) with ethylene oxide in order to obtain a neutralized matrix of non-antigenic collagenous material. The invention also relates to the matrices obtained and to surgical implants comprising such matrices.

Description

Method for preparing neutralized matrix of non-antigenic collagenous material
The present invention relates to a method for preparing neutralized matrices of non-antigenic collagenous material showing good tensile strength. The invention further relates to matrices obtained by this method and to surgical implants, for example hernia repair implants or haemostats, comprising such matrices.
Collagen based matrices in general are particularly useful for the manufacture of implants in the medical field. Such matrices are usually obtained by lyophilisation of a collagen solution. Lyophilization involves a first step during which a solution is frozen in a particular structure, and then a second step, during which a controlled pressure is applied in order to cause sublimation of the water present in the frozen structure. At the end of the sublimation step, only the constituents present in the initial solution remain, thus producing a porous structure.
Indeed, the porous structure of such collagen matrices is of particular interest in the manufacture of surgical implants for many reasons. When the implant is intended to repair a tissue defect, for example in the case of a hernia in the abdominal wall, a porous structure favors cell colonization and therefore reconstruction of the biological tissue. Alternatively, when the implant is intended to be used as a haemostatic patch, in order to stop bleeding, the porous structure allows efficiently absorbing biological fluids, like blood.
Nevertheless, these reinforcing implants and haemostatic patches must also show very good mechanical properties, such as a high tensile strength, and good handling characteristics.
Various collagenous preparations have been suggested for the manufacture of surgical implants. These preparations have comprised dispersions, solutions and gels of collagen, as well as reconstituted and spongy forms of collagen. These preparations were most often prepared by digesting collagen of animal origin with a proteolytic enzyme active under acidic conditions. The collagenous material is solubilised in the acidic media and can be filtered from any debris and insoluble skin components. The solubilised collagen may be reconstituted as a solid, gel or sponge by raising the pH of the solution and stabilising by cross-linking. However, the natural structure of the collagen is lost in the process. The resulting preparations tend to have little or no tensile strength, are amorphous in structure and show a propensity for being reabsorbed, either disappearing from the site of injection or implantation or being replaced by scar tissue.
A different class of collagenous materials, herein after called "non- antigenic collagenous material" in the present application, are those in which the basic structure of the natural collagen, for example from skin, is maintained, which are substantially free of antigenic non-fibrous tissue proteins and which are substantially free of antigenic polysaccharides, mucopolysaccharides and glycoproteins. The preparation of such non-antigenic collagenous materials is described in GB 1 565 340, US 5, 397, 353 and US 6, 936, 271 .
In the present application, by "material substantially free of a compound" is meant that the material contains less than 5%, preferably less than 1 % in weight of said compound.
The preparation of non-antigenic collagenous material may comprise treating fibrous tissue of human or animal origin with two enzymes, one of said enzymes being a proteolytic enzyme which will under certain conditions remove the non-fibrous tissue proteins, and the other of said enzymes being a carbohydrate-splitting enzyme which will under certain conditions remove antigenic polysaccharide, mucopolysaccharides and glycoproteins from the tissue. Non-antigenic collagenous material, in particular obtained as described above, has low or absent antigenicity. Any residual antigenicity in the tissue may be removed therefrom by reacting it with a cross- linking agent which will under certain conditions form a link between the terminal amino groups of lysine groups in the tissue. Crosslinking agents may be glutaraldehyde, formalaldehyde and nitrous acid.
When homografted between individuals of the same species or heterografted between individuals of a different species, non-antigenic collagenous material does not elicit immunological rejection reactions or foreign body reactions. Non-antigenic collagenous material is particularly stable and strong. In addition, the original architecture of the collagenous fibrous material is preserved. In particular, in a non-antigenic collagenous material, the telopeptides of the collagen are kept intact. The material is neither solubilised nor denatured in the process so its natural structure is maintained which makes an implant derived from the material feel natural rather than an inert material. Non-antigenic collagenous material is capable of being infiltrated and colonized by the host cells of another individual of the same or different species and revascularized to form a repair implant for example.
Non-antigenic collagenous material may be prepared under the form of a sheet material, of a cryomilled powder or also as a powdered lyophilised form.
Non-antigenic collagenous material is therefore of particular interest for surgical applications. It would be interesting to provide matrices of non- antigenic collagenous material in order to use them in the manufacture of surgical implants, such as for example hernia repair implants or haemostatic patches.
Anyway, in order to manufacture matrices of non-antigenic collagenous material, a solution of such material must be prepared and then lyophilised.
Non-antigenic collagenous material, regardless from the form under which it is prepared, is not soluble at neutral pH and may be solubilised in an acidic solution only. The matrices obtained by lyophilisation of these acidic solutions are also acidic.
It has been observed that, when put in neutral aqueous conditions, the acidic matrices of non-antigenic collagenous material dissolve completely. These re-solubilizations result in the total destruction of the matrix which can therefore no longer be used in the manufacture of a reinforcement implant or of a haemostatic patch. The acidic matrix may neither be used as a finished product by a surgeon in this state because it would not fulfil its function. Indeed, the acidic matrix of non-antigenic collagenous material loses all mechanical strength once put in the medium, such as biological fluids, in which it is intended to be implanted.
In addition, acidic matrices may cause biocompatibility problems with adjacent biological tissue once implanted in a patient body.
It would be desirable to provide a method for preparing matrices of non-antigenic collagenous material capable of maintaining their handling characteristics when put in contact with a neutral medium such as biological fluids, so that such matrices may be used in the manufacture of implants such as hernia repair implants or haemostatic patches.
In particular, it would be desirable to implement a method of preparing matrices of non-antigenic collagenous material that would make it possible to efficiently neutralize such matrices in order to prepare effective surgical implants for reinforcing abdominal walls for example or for haemostatic purposes.
The Applicant has found that by performing a specific sterilization step on matrices obtained by lyophilisation of an acidic solution of non- antigenic collagenous material, it was possible to efficiently neutralize and sterilize such matrices at the same time, while enhancing their mechanical properties, in particular their tensile strength.
A first aspect of the present invention is a method for preparing a neutralized matrix of non-antigenic collagenous material comprising the steps of :
- a) preparing an acidic solution of non-antigenic collagenous material,
- b) pouring the solution of a) into a mould in order to form a layer, - c) lyophilizing the layer of b) in order to obtain an acidic matrix of non-antigenic collagenous material,
d) sterilizing the acidic matrix obtained in c) with ethylene oxide in order to obtain a neutralized matrix of non-antigenic collagenous material.
The method according to the invention makes it possible to obtain neutralized matrices of non-antigenic collagenous material showing excellent mechanical properties such as tensile strength. In particular, the method of the invention allows performing the neutralization and the sterilization of the matrices in a single step. The method of the invention allows therefore saving at least one step in the manufacturing process of a collagen matrices, namely of a matrix of non-antigenic collagenous material. The manufacturing process is therefore rendered particularly simple. Time is saved and opportunities of making mistakes are decreased with respect to a method where the neutralization step and the sterilization step are two separate steps. The matrices of non-antigenic collagenous material obtained by means of the method according to the invention have excellent tensile strength. They also show good handling characteristics. They therefore make it possible to obtain particularly effective surgical implants, for example for reinforcing the abdominal wall. The matrices obtained by the method of the invention are also particularly useful in the manufacture of haemostats such as haemostatic patches. The matrices obtained by the method of the invention may also be used as scaffolds for cell culture. The matrices obtained by the method of the invention may be used on their own or in combination with a textile or with any other element, such as for example a film, a matrix of same or different composition.
Another aspect of the invention is a matrix obtained by the method of the invention. The matrices obtained by the method of the invention show in particular a tensile strength much greater than that of matrices prepared according to steps a)-c) above but which have not been sterilized according to step d). An aspect of the invention is therefore a neutralized matrix of non- antigenic collagenous material obtained by the method of the invention. An aspect of the invention is a neutralized matrix of non-antigenic collagenous material obtained by the method of the invention, having a tensile strength, for example measured according to standard ASTM D0638-03 with type IV specimen, at least two times greater, preferably three times greater, than that of the non sterilized matrix.
According to a first step of the method according to the invention, step a), an acidic solution of non-antigenic collagenous material is prepared.
As seen above, "non-antigenic collagenous material" in the present application, means a collagenous material in which the basic structure of the natural collagen, for example from skin, is maintained, which is substantially free of antigenic non-fibrous tissue proteins and which is substantially free of antigenic polysaccharides, mucopolysaccharides and glycoproteins. The preparation of such non-antigenic collagenous materials is described in GB 1 565 340, US 5, 397, 353 and US 6, 936, 271 .
In the present application, by "material substantially free of a compound" is meant that the material contains less than 5%, preferably less than 1 % in weight of said compound.
The preparation of non-antigenic collagenous material may comprise treating fibrous tissue of human or animal origin with two enzymes, one of said enzymes being a proteolytic enzyme which will under certain conditions remove the non-fibrous tissue proteins, and the other of said enzymes being a carbohydrate-splitting enzyme which will under certain conditions remove antigenic polysaccharide, mucopolysaccharides and glycoproteins from the tissue. Non-antigenic collagenous material, in particular obtained as described above, has low or absent antigenicity. Any residual antigenicity in the tissue may be removed therefrom by reacting it with a cross- linking agent which will under certain conditions form a link between the terminal amino groups of lysine groups in the tissue. Crosslinking agents may be glutaraldehyde, formalaldehyde and nitrous acid.
When homografted between individuals of the same species or heterografted between individuals of a different species, non-antigenic collagenous material does not elicit immunological rejection reactions or foreign body reactions. Non-antigenic collagenous material is particularly stable and strong. In addition, the original architecture of the collagenous fibrous material is preserved. In particular, in a non-antigenic collagenous material, the telopeptides of the collagen are kept intact. The material is neither solubilised nor denatured in the process so its natural structure is maintained which makes an implant derived from the material feel natural rather than an inert material.
Non-antigenic collagenous material is capable of being infiltrated and colonized by the host cells of another individual of the same or different species and revascularized to form a repair implant for example.
Non-antigenic collagenous material may be prepared under the form of a sheet material, of a cryomilled powder or also as a powdered lyophilised form.
Non-antigenic collagenous material may also preferably be substantially free of cellular elements. In this view, the fibrous tissue is purified so that all cellular elements such as sweat glands, sebaceous glands and vascular tissue are removed thus eliminating cyst formation and foreign body reactions when subsequently implanted in a body. Such a purification process is described in US 5, 397, 353.
Non-antigenic collagenous material may also preferably be substantially free of lipids and lipid residues. In this view, the fibrous tissue may be further treated in order to remove the lipid portions from the tissue, for example by using a selective enzyme such as a lipase or alternatively by solvent extraction using an organic solvent. Such a process for removing the lipids and lipid residues from the non-antigenic collagenous material is described in US 5, 397, 353.
The fibrous tissue may further be treated by polyisocyanates in order to obtain non-antigenic collagenous material preparations having particularly low cytotoxicity. Such non-antigenic collagenous material shows a good inertness with respect to adjacent biological tissue when implanted. Non-antigenic collagenous materials suitable as starting compounds for the method according to the invention are for example described in US 5, 397, 353 and US 6, 936, 271 .
The acidic solution of step a) of the method according to the invention is generally prepared by solubilization of non-antigenic collagenous material in powder or fibrous form in water. The solution is adjusted to the desired pH, for example by adding chlorhydric acid or acetic acid, either before or after introduction of the non-antigenic collagenous material. In one embodiment of the method according to the invention, the pH of the solution is adjusted to a value ranging from about 2.0 to about 4.0, preferably from about 3.0 to about 3.5, more preferably to about 3.4, for example by adding chlorhydric acid or acetic acid.
Such pHs for the solution of step a) make it possible to obtain, in the end, matrices which have particularly good tensile strength.
In one embodiment of the method according to the invention, the solution of step a) is a solution of non-antigenic collagenous material in acidic water, the concentration of non-antigenic collagenous material in said solution ranging from 0.1 to 10%, preferably from 0.5% to 3%, and more preferably about 1 % by weight, relative to the total weight of the solution.
Such concentrations make it possible to obtain, in the end, matrices which have particularly good tensile strength. Also preferably, the solution of the method according to the invention is free of any other polymer than the non-antigenic collagenous material.
According to a second step of the method according to the invention, step b), the acidic solution of non-antigenic collagenous material is poured into a mould in order to form a layer. Generally, the mould is in the shape of a rectangle having dimensions compatible with the use of the matrix obtained as all or part of a reinforcing implant for the abdominal wall or of a haemostatic patch.
According to a third step of the method according to the invention, step c), the layer obtained in b) is lyophilized so as to obtain a matrix.
In the present application, the term "matrix" is intended to mean a layer which has pores, or gaps, alveoli, holes, orifices, which are evenly or unevenly distributed not only at the surface, but also within the thickness of said layer, and which are more or less interconnected, depending on the lyophilization process used. Such lyophilization processes are known. It is known practice to vary the freezing temperature and speed and also the characteristics of the polymer solution to be lyophilized (pH, concentration, etc.), in this case non-antigenic collagenous material, as a function of the structure of the matrix that it is desired to obtain (see US 4 970 298; Doillon et al, J Biomed Mater Res, 1986; Schoof, J Biomed Mater Res, 2001 ; O'Brien et al, Biomaterials, 2004).
In embodiments, in step c), the layer is frozen during a time ranging from 3 to 15 hours. In embodiments, in step c), the frozen layer is primary dried during a time ranging from 7 to 15 hours.
The matrix obtained by the lyophilization of the layer of acidic solution of non-antigenic collagenous material is acidic, in other words has an acidic extractible pH. Such an extractible pH may vary from 3 to 5, and for example is 4.
According to a fourth step of the method according to the invention, step d), the matrix obtained in c) is sterilized with ethylene oxide.
In a first stage of the sterilization step, the matrix may be preconditioned in order to make sure that it is at a uniform temperature and humidity. In this view, the matrix is put in a cell and may be exposed during a determined time, ranging for example from 8 to 15 hours, to a warm and humid environment. The temperature may range from about 28°C to about 32°C. The relative humidity may range from about 50 to about 80%.
In a second stage of the sterilization process, the cell is evacuated and the ethylene oxide is introduced. In embodiments, in step d), the matrix is exposed to ethylene oxide for a time that may range from about 10 to about 1 1 hours. During this time, a certain amount of ethylene oxide, for example from 1 .6 to 2 kg, is injected. In embodiments, in step d), the ethylene oxide is injected at a pressure that may range from 70000 Pa to 78000 Pa. The temperature and relative humidity may be the same as in the first stage.
In a third stage, ethylene oxide is removed and air replaces the ethylene oxide in the cell .
At the end of the sterilization step, the sterilized matrix of non- antigenic collagenous material may show an extractible pH of about 7.0-7.4.
This sterilization step has as a consequence that the pH of the matrix of non-antigenic collagenous material is increased to about 7.0-7.4, in particular is increased from about 3.0-4.0 to about 7.0-7.4. The sterilized matrix is therefore neutralized during the sterilization with the ethylene oxide. The sterilization and the neutralization of the matrix therefore occur in one single step. The method of the invention therefore allows saving an operation step with respect to methods of the prior art in which the sterilization step and the neutralization step are two separate operations.
The matrix of non-antigenic collagenous material which has been neutralized and sterilized according to the method of the invention can be part of, or constitute, the whole of a surgical implant, for example an abdominal wall reinforcement or of an haemostatic patch. Indeed, these neutralized and sterilized matrices have excellent tensile strength.
Another aspect of the invention relates to a surgical implant, such as an abdominal wall reinforcement, for example a hernia repair implant, or an haemostat such as a haemostatic patch, comprising at least one neutralized matrix of non-antigenic collagenous material obtained by the method described above. An aspect of the invention relates to a hernia repair implant comprising at least one neutralized matrix of non-antigenic collagenous material obtained by the method described above. For example, the hernia repair implant may consist in a neutralized matrix of non-antigenic collagenous material obtained by the method described above. An aspect of the invention relates to a haemostat comprising at least one neutralized matrix of non-antigenic collagenous material obtained by the method described above. For example, the haemostat may consist in a neutralized matrix of non-antigenic collagenous material obtained by the method described above.
Another aspect of the invention is a method for increasing the tensile strength of a matrix of non-antigenic collagenous obtained by:
- a) preparing an acidic solution of non-antigenic collagenous material,
- b) pouring the solution of a) into a mould in order to form a layer,
- c) lyophilizing the layer of b) in order to obtain an acidic matrix of non-antigenic collagenous material,
said method comprising the step of sterilizing the acidic matrix obtained in c) with ethylene oxide.
The invention and the advantages thereof will emerge more clearly from the example below and the appended figure in which: Figure 1 is a graph comparing the tensile strengths of a matrix obtained with the method of the invention and of two other matrices not obtained with the method of the invention.
EXAMPLE 1 :
Non-antigenic collagenous material, similar to that described at example 5 of US 6, 936, 271 , except for the crosslinking step, is provided, under the form of powder.
A solution of non-antigenic collagenous material at 1 % (w/w) in water is prepared and adjusted to about pH 4.0 by addition of HCI .
121 g of this solution is poured into a rectangular mould of dimensions of 12 cm X 17 cm, so as to form a layer of the solution.
The layer is lyophilised for about 24 hours, with a freezing step of 4 hours, and a primary drying step of 8 hours. A matrix of non-antigenic collagenous material is obtained. This matrix is acidic, i.e. this matrix has an extractible pH of about 5.2.
The matrix is then sterilized with ethylene oxide according to the following process.
In a first stage, the matrix is put in a cell and is exposed during 8-15 hours to a warm and humid environment with the following parameters :
- Temperature : 28-32°C
- Relative humidity : 50-80%
In a second stage, the cell is evacuated and the ethylene oxide is introduced. The matrix is exposed to ethylene oxide for approximately 10-1 1 hours. During this time, 1 .6 to 2 kg of ethylene oxide is injected. The ethylene oxide injection pressure ranges from 70000 to 78000 Pa. The temperature and relative humidity are the same as in the first stage. In a third stage, ethylene oxide is removed.
The sterilized matrix obtained shows an extractible pH of about 7.0. As a consequence, the sterilization of the matrix with ethylene oxide has led to an increase of the extractible pH of the matrix from about 5.2 to about 7.0.
The sterilized matrix of non-antigenic collagenous material is therefore neutralized. Such a matrix may be used for the manufacture of a surgical implant such as an abdominal reinforcement or a haemostatic patch with no risk that the matrix dissolves or collapses at the contact of a neutral medium such as the biological fluid.
In addition, the sterilized and neutralized matrix obtained shows very good tensile strength. In particular, the sterilized matrix shows a higher tensile strength than the non sterilized matrix.
Comparative tests:
The tensile strengths of the matrix of the present example before sterilization (comparative referenced N/A), after sterilization with ethylene oxide (invention referenced EtO), and of a matrix of same composition of that of the present example but neutralized with ammonia (comparative reference Ammonia) have been measured according to the test described in standard ASTM D0638-03 with type IV specimen.
With reference to Figure 1 , are shown :
- the tensile strength of the matrix of the present example before sterilization (reference N/A on the graph),
- the tensile strength of the matrix of the present example after sterilization with ethylene oxide (referenced EtO on the graph), and
- the tensile strength of a matrix of same composition of that of the present example but neutralized with ammonia (referenced Ammonia). The results are collected in the following table :
As shown on this graph, the tensile strength of the matrix obtained by the method of the invention is at least two times, and is even about three times, greater than that of the non sterilized matrix. In addition, the tensile strength of the matrix obtained by the method of the invention is about twice greater than that of a matrix neutralized by Ammonia.
EXAMPLE 2 :
Non-antigenic collagenous material, similar to that described at example 5 of US 6, 936, 271 , except for the crosslinking step, is provided, under the form of powder.
A solution of non-antigenic collagenous material at 1 % (w/w) in water is prepared and adjusted to about pH 3.4 by addition of CH3COOH.
121 g of this solution is poured into a rectangular mould of dimensions of 12 cm X 17 cm, so as to form a layer of the solution.
The layer is lyophilised for about 24 hours, with a freezing step of 4 hours, and a primary drying step of 8 hours.
A matrix of non-antigenic collagenous material is obtained. This matrix is acidic, i.e. this matrix has an extractible pH of about 5.1 .
The matrix is then sterilized with ethylene oxide according to the following process. In a first stage, the matrix is put in a cell and is exposed during 8-15 hours to a warm and humid environment with the following parameters :
- Temperature : 28-32°C
- Relative humidity : 50-80%
In a second stage, the cell is evacuated and the ethylene oxide is introduced. The matrix is exposed to ethylene oxide for approximately 10-1 1 hours. During this time, 1 .6 to 2 kg of ethylene oxide is injected. The ethylene oxide injection pressure ranges from 70000 to 78000 Pa. The temperature and relative humidity are the same as in the first stage.
In a third stage, ethylene oxide is removed.
The sterilized matrix obtained shows an extractible pH of about 7.0- 7.4. As a consequence, the sterilization of the matrix with ethylene oxide has led to an increase of the extractible pH of the matrix from about 5.1 to about 7.0-7.4.
The sterilized matrix of non-antigenic collagenous material is therefore neutralized. Such a matrix may be used for the manufacture of a surgical implant such as an abdominal reinforcement or a haemostatic patch with no risk that the matrix dissolves or collapses at the contact of a neutral medium such as the biological fluid. The tensile strengths of the matrix of the present example before sterilization and after sterilization with ethylene oxide have been measured according to the test described in standard ASTM D0638-03 with type IV specimen.
The results are collected in the following table
Sample Matrix (before Matrix (after EtO
sterilization) sterilization)
Tensile strength 0.28 0.78
in Newton As shown on this graph, the tensile strength of the matrix obtained by the method of the invention is at least twice, and is even about 2.8 times, greater than that of the non sterilized matrix.

Claims

1 . Method for preparing a neutralized matrix of non-antigenic collagenous material comprising the steps of
- a) preparing an acidic solution of non-antigenic collagenous material,
- b) pouring the solution of a) into a mould in order to form a layer,
- c) lyophilizing the layer of b) in order to obtain an acidic matrix of non-antigenic collagenous material,
- d) sterilizing the acidic matrix obtained in c) with ethylene oxide in order to obtain a neutralized matrix of non-antigenic collagenous material.
2. Method according to claim 1 , in which the solution of step a) is a solution of non-antigenic collagenous material in acidic water, the non-antigenic collagenous material concentration in said solution ranging from 0.1 to 10%, preferably from 0.5% to 3%, and more preferably is 1 % by weight, relative to the total weight of the solution.
3. Method according to claim 1 or 2, in which the pH of the solution in a) is adjusted to a value ranging from about 2.0 to about 4.0, preferably from about 3.0 to about 3.5, more preferably to about 3.4, for example by adding chlorhydric or acetic acid.
4. Method according to any one of claims 1 to 3, in which the solution of step a) is free of any other polymer than the non-antigenic collagenous material.
5. Method according to any one of claims 1 -4, wherein, in step c), the layer is frozen during a time ranging from 3 to 15 hours.
6. Method according to claim 5, wherein the frozen layer is primary dried during a time ranging from 7 to 15 hours.
7. Method according to any one of claims 1 -6, wherein, in step d), the matrix is exposed to ethylene oxide for a time ranging from about 10 to about 1 1 hours.
8. Method according to any one of claims 1 -7, wherein the ethylene oxide is injected at a pressure ranging from 70000 Pa to 78000 Pa.
9. Neutralized matrix of non-antigenic collagenous material obtained by the method of any one claims 1 to 8.
10. Neutralized matrix according to claim 9, having a tensile strength at least two times greater than that of the non sterilized matrix.
1 1 . Neutralized matrix according to claim 10, having a tensile strength about three times greater than that of the non sterilized matrix.
12. Surgical implant comprising at least one neutralized matrix of non-antigenic collagenous material according to any one of claims 9-1 1 .
13. Hernia repair implant comprising at least one neutralized matrix of non-antigenic collagenous material according to any one of claims 9-1 1 .
14. Haemostat comprising at least one neutralized matrix of non- antigenic collagenous material according to any one of claims 9-1 1 .
EP15725376.6A 2014-05-30 2015-06-01 Method for preparing neutralized matrix of non-antigenic collagenous material Active EP3148599B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305809 2014-05-30
PCT/EP2015/062169 WO2015181395A1 (en) 2014-05-30 2015-06-01 Method for preparing neutralized matrix of non-antigenic collagenous material

Publications (2)

Publication Number Publication Date
EP3148599A1 true EP3148599A1 (en) 2017-04-05
EP3148599B1 EP3148599B1 (en) 2019-12-18

Family

ID=50942636

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15725376.6A Active EP3148599B1 (en) 2014-05-30 2015-06-01 Method for preparing neutralized matrix of non-antigenic collagenous material

Country Status (3)

Country Link
US (1) US10052400B2 (en)
EP (1) EP3148599B1 (en)
WO (1) WO2015181395A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3059255B1 (en) * 2015-02-17 2020-05-13 Sofradim Production Method for preparing a chitosan-based matrix comprising a fiber reinforcement member
CN113463385B (en) * 2021-07-19 2022-05-20 四川大学 High-strength and high-toughness collagen fiber matrix, framework material, structural material and preparation method thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3810473A (en) 1972-12-04 1974-05-14 Avicon Inc Liquid-laid, non-woven, fibrous collagen derived surgical web having hemostatic and wound sealing properties
US3919773A (en) 1973-12-20 1975-11-18 Sybron Corp Direct moldable implant material
GB1565340A (en) 1978-04-25 1980-04-16 Grant R A Fibrous tussue preparations
US4534761A (en) 1981-08-14 1985-08-13 Bentley Laboratories, Inc. Implant device
IL74715A0 (en) 1984-03-27 1985-06-30 Univ New Jersey Med Biodegradable matrix and methods for producing same
GB8413319D0 (en) 1984-05-24 1984-06-27 Oliver Roy Frederick Biological material
IL76079A (en) 1985-08-13 1991-03-10 Univ Ramot Collagen implants
US4986831A (en) 1988-04-25 1991-01-22 Angeion Corporation Medical implant
US5192311A (en) 1988-04-25 1993-03-09 Angeion Corporation Medical implant and method of making
US5785983A (en) 1991-05-23 1998-07-28 Euroresearch Srl Non-porous collagen sheet for therapeutic use, and the method and apparatus for preparing it
CA2070586C (en) 1991-06-10 1995-11-28 Barry Eppley Prosthetic implant
US6015844A (en) 1993-03-22 2000-01-18 Johnson & Johnson Medical, Inc. Composite surgical material
US6001895A (en) 1993-03-22 1999-12-14 Johnson & Johnson Medical, Inc. Composite surgical material
US6342484B1 (en) 1993-06-30 2002-01-29 Board Of Regents, The University Of Texas Systems Method and compositions for promotion of wound treatment
US5891558A (en) 1994-11-22 1999-04-06 Tissue Engineering, Inc. Biopolymer foams for use in tissue repair and reconstruction
AUPN174495A0 (en) 1995-03-15 1995-04-06 Ketharanathan, Vettivetpillai Surgical prostheses
US5676967A (en) 1995-04-18 1997-10-14 Brennen Medical, Inc. Mesh matrix wound dressing
US6833408B2 (en) 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
DE69636289T2 (en) 1995-12-18 2007-05-10 Angiodevice International Gmbh NETWORKED POLYMERISATE MATERIALS AND METHOD FOR THEIR USE
TW501934B (en) 1996-11-20 2002-09-11 Tapic Int Co Ltd Collagen material and process for making the same
US20020086423A1 (en) 1997-09-09 2002-07-04 Toshiaki Takezawa Hydrogel thin film containing extracellular matrix components
US6004333A (en) 1997-10-31 1999-12-21 Ethicon Endo-Surgery, Inc. Prosthetic with collagen for tissue repair
GB2345638A (en) 1998-09-11 2000-07-19 Tissue Science Lab Limited Injectable collagen compositions
FR2792824B1 (en) 1999-04-27 2001-06-22 Sofradim Production DEVICE FOR TREATING PROLAPSUS BY VAGINAL SUSPENSION
US6699470B1 (en) 1999-10-12 2004-03-02 Massachusetts Institute Of Technology Mesh-gel constructs for cell delivery containing enzymes and/or enzyme inhibitors to control gel degradation
US6368859B1 (en) 1999-12-29 2002-04-09 Children's Medical Center Corporation Methods and compositions for producing a fascial sling
US20010053839A1 (en) 2000-06-19 2001-12-20 Koken Co. Ltd. Biomedical material and process for making same
IT1318663B1 (en) 2000-08-02 2003-08-27 Mediolanum Farmaceutici Srl TWO-SIDED COLLAGEN MEMBRANES, ONE OF WHICH ORGANIZED AT THE MACRO-MOLECULAR LEVEL.
US6296607B1 (en) 2000-10-20 2001-10-02 Praxis, Llc. In situ bulking device
DE10050199A1 (en) 2000-10-11 2002-04-25 Ethicon Gmbh Areal implant having a flexible basic structure on a polymer basis, contains ultrasonically detectable elements, which contain or produce gas and set up for detectability for at least four weeks after implantation
US20110168192A9 (en) 2000-12-20 2011-07-14 Eduardo Fierro Adjustable autofixing sling for treatment of urinary incontinence
US20020127265A1 (en) 2000-12-21 2002-09-12 Bowman Steven M. Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration
US6599323B2 (en) 2000-12-21 2003-07-29 Ethicon, Inc. Reinforced tissue implants and methods of manufacture and use
CA2365376C (en) 2000-12-21 2006-03-28 Ethicon, Inc. Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration
US6852330B2 (en) 2000-12-21 2005-02-08 Depuy Mitek, Inc. Reinforced foam implants with enhanced integrity for soft tissue repair and regeneration
CN1265845C (en) 2001-07-30 2006-07-26 株式会社日本组织工程 Tissue regenerating base material, implanting material and method of producing the same
US6645250B2 (en) 2001-10-30 2003-11-11 Carl W. Schulter Biocompatible form and method of fabrication
US6736823B2 (en) 2002-05-10 2004-05-18 C.R. Bard, Inc. Prosthetic repair fabric
US6773440B2 (en) 2002-07-02 2004-08-10 Satiety, Inc. Method and device for use in tissue approximation and fixation
AU2003268127A1 (en) 2002-08-20 2004-03-11 Richard L. Grant Compositions comprising epithelial cells for the treatment and prevention of tissue adhesions
US8142515B2 (en) 2002-11-04 2012-03-27 Sofradim Production Prosthesis for reinforcement of tissue structures
US20040105880A1 (en) 2002-11-21 2004-06-03 Turner Josephine Sara Interpenetrating polymer network
CN1732023A (en) 2002-12-27 2006-02-08 血管技术国际股份公司 Compositions and methods of using collajolie
KR100676285B1 (en) * 2005-03-11 2007-01-30 세원셀론텍(주) Manufactured product using and collagen solution manufacturing method and collagen separation method of animal tissue
WO2013116744A1 (en) * 2012-02-01 2013-08-08 Children's Medical Center Corporation Biomaterial for articular cartilage maintenance and treatment of arthritis

Also Published As

Publication number Publication date
US10052400B2 (en) 2018-08-21
US20170189574A1 (en) 2017-07-06
EP3148599B1 (en) 2019-12-18
WO2015181395A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
US9642937B2 (en) Preparation method for implantable medical biological materials of animal origin
USRE48536E1 (en) Collagen sponge
Lee et al. Characterization of UV-irradiated dense/porous collagen membranes: morphology, enzymatic degradation, and mechanical properties
WO2016180259A1 (en) Dry animal-derived collagen fiber tissue material and preparation method and bioprosthesis thereof
Bielli et al. Characterization of a new decellularized bovine pericardial biological mesh: Structural and mechanical properties
US20220126000A1 (en) Mesh-based in situ cross-linkable compositions
KR20010052714A (en) Collagen Material and Process for Producing the Same
CN106880872B (en) Natural extracellular matrix biomembrane and the preparation method and application thereof
KR20140037271A (en) Anti-adhesion medical material and method for producing same
CN103189035A (en) Anti-adhesion alginate barrier of variable absorbance
Bao et al. Agar/collagen membrane as skin dressing for wounds
KR20170073673A (en) A biomaterial scaffold for regenerating the oral mucosa
CN113663137B (en) Composite biological patch and preparation method and application thereof
Ayala et al. Evaluation of a bioengineered construct for tissue engineering applications
CN111084900A (en) Preparation method and application of acellular fish skin matrix
Zhang et al. Additively manufactured macroporous chambers facilitate large volume soft tissue regeneration from adipose-derived extracellular matrix
KR101573838B1 (en) Artificial biomembrane using Cocoon and Method for manufacturing thereof
US10052400B2 (en) Method for preparing neutralized matrix of non-antigenic collagenous material
CN107715181A (en) A kind of preparation method of biodegradable organization engineering skin support
KR101602797B1 (en) Artificial biomembrane using silk matrix and Method for manufacturing thereof
KR102182882B1 (en) Porcine Dermis-derived Barrier Membrane for Dental Applications and Method for Fabricating the Same
US20090227773A1 (en) Process for the production of collagen material
KR101742594B1 (en) Preparation Method of a Dental Collagen Membrane with Improved Durability and a Dental Collagen Membrane Prepared Thereby
CN111359020B (en) Soft tissue repair material and preparation method and application thereof
KR102182883B1 (en) Collagen Membrane and Method for Fabricating the Same

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20161212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180516

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190731

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015043846

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1213870

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200115

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200319

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200418

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20200525

Year of fee payment: 6

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015043846

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1213870

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191218

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

26N No opposition filed

Effective date: 20200921

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200601

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20210601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230523

Year of fee payment: 9

Ref country code: DE

Payment date: 20230523

Year of fee payment: 9